跳至主要内容
临床试验/NCT00873262
NCT00873262Unknown2 期

A Phase II Randomized, Two-arms, Single-blind, Cross Controlled Study for Evaluation the Safety and Efficacy of Diagnosis and Treatment of Premenstrual Syndrome by Detecting Skin Reactions Followed by Desensitization to Sex Hormones

EVE Medical Systems Ltd.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2009年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
20
试验地点
1
主要终点
To assess the efficacy of hormonal desensitization compared to solvent treatment in reduction of the PMS symptoms severity and length of PMS by subjects with severe PMS symptoms (according to criteria of PMS).

研究概览

简要总结

The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS) and desensitizes them with the relevant sex hormones in order to reduce PMS symptoms.

The system includes skin testing panel for identification of hormones to which the patients might be sensitive. Tests are applied close to the ovulation period and the skin reaction is examined in 20 minutes, 48 hours and daily during the following month. Results of skin tests and patient's history will determine the eligibility of the patients to enter a desensitization protocol.

During the desensitization period hormones to which the patient were found sensitive to, are injected intradermally three times (once a month) within the luteal phase in increasing doses. The end-point of the study is a statistically significant decrease, or elimination of PMS symptoms, compared to a solvent group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Person is over the age of 20 but not older than age
  • Person is willing to participate as evidenced by signing the written informed consent form.
  • Suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10 according to standard scale of PMS symptoms severity)
  • Other severe symptoms of Premenstrual syndrome (based on WHO and ACOG criteria). This may include one or more of PMS symptoms with level 7-10 according to standard scale of PMS symptoms severity.
  • At work, school, home, or in daily routine, at least one of the PMS symptoms caused reduction of productivity or inefficiency
  • At least one of the PMS symptoms caused avoidance of or less participation in hobbies or social activities
  • At least one of the PMS symptoms interfere with relationships with others
  • Timing of PMS symptom(s): during the 14 days prior to onset of menstrual flow (rather than spotting) and up to 5 days during the menstrual flow.
  • Pattern and length of PMS symptomatic period: minimum of 2 days, up to 14 days.
  • For PMS diagnosis two out of last three consecutive menstrual cycles were monitored by daily monitoring of symptoms.
  • Timing and length of asymptomatic phase: day 6 to at least day 10 of the menstrual cycle.
  • Cyclicity - presentation of the 'off-on' phenomenon: there should be a clear shift from no PMS symptoms to PMS symptoms.
  • Reliable non hormonal contraception.

排除标准

  • Pregnant or lactating woman
  • Oral contraceptives during last three months, including hormonal IUD (trade name mirena).
  • Serious health problems.
  • Unexplained menstrual disorders.
  • Treated by hormones (estrogen and progesterone).

研究组 & 干预措施

Hormones

Active Comparator

干预措施: Skin test panel and desensitization kit (Drug)

Solvent

Placebo Comparator

干预措施: Skin test panel and solvent (Drug)

结局指标

主要结局

To assess the efficacy of hormonal desensitization compared to solvent treatment in reduction of the PMS symptoms severity and length of PMS by subjects with severe PMS symptoms (according to criteria of PMS).

时间窗: 5-6 months

次要结局

  • To assess the efficacy of hormonal desensitization compared to solvent treatment in reduction of the breast swelling and tenderness in 4 weeks of treatment.(2-3 months)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验